Skip to main content
  • English
  • Català
  • Español
Home
  • Company
    • Overview & History
    • Team
    • Join Oryzon
  • Epigenetics
    • Histone Code Hypothesis
    • Modulator Enzymes
    • LSD1 & Disease
    • Technology Platforms
    • Scientific Publications by Oryzon
  • Therapeutic Programs
    • Strategy
    • LSD1 & Cancer
    • Oryzon's Pipeline
  • Collaborative Research
    • Collaborative Projects
  • For Patient
    • Patient Information
  • Shareholders and Investors
    • Investor Information and News
    • Share Information
    • Events & Presentations
    • Financial Information & Downloads
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Press Releases
  • Contact
    • General Contact
    • Investor Contact
    • Email Alerts

News

Archive

  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010

News & Press Releases

6 December 2016
ORYZON Announces Encouraging Top-line Results from Phase I-IIA Clinical Trial in Acute Leukemia of RG6016 (ORY-1001) at the American Society of Hematology 2016 Annual Meeting
14 November 2016
ORYZON to Present Clinical Data on LSD1 Inhibitor ORY-1001 at ASH 2016
7 November 2016
ORYZON Announces Exercise of Warrants by Alzheimer’s Drug Discovery Foundation (ADDF)
26 October 2016
ORYZON Genomics to Present at Stifel 2016 Healthcare Conference
24 October 2016
ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2016
29 September 2016
ORYZON AT BIOSPAIN 2016
26 September 2016
ORYZON Closes € 5.3 Million (6 M USD) in additional Debt Financing
14 September 2016
ORYZON Selected as one of the Finalist for the 7th Annual Most Innovative EU Biotech SME Award
12 September 2016
Oryzon to Present ORY-2001 Preclinical efficacy data in Multiple Sclerosis animal model at ECTRIMS-2016 Annual Meeting
1 September 2016
Oryzon Genomics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference and at BioPharm America 2016

Pages

  • « first
  • ‹ previous
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • next ›
  • last »

epigen-logo

Epigenetic drugs for a better world.

United States

Oryzon Corporate
245 First Street, Suite 1800
Cambridge, MA 02142

T: (617) 444-8786
F: (617) 444- 8405
info@oryzon.com

Spain

Oryzon Genomics
Sant Ferran 74
08940 Cornellà de Llobregat, Barcelona, Spain

T: (+34) 93 515 1313
F: (+34) 93 377 4028
info@oryzon.com

Legal Advice
Privacy Policy

Investor Information

ISIN: ES0167733015 - ORY

Please contact us for investor information.

Contact Us

© 2019

Oryzon Genomics

All Rights Reserved

  • Legal Advice
  • Privacy Policy
  • Registered address: Carrera de San Jerónimo 15, 2ª planta, 28014 Madrid (Spain)